Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | terminated | Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 |
| clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01374087 | Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer(ANABRAQ) | terminated | Phase 2 | 32 | IpsenINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02710422 | Miami Membrane for Potency (MMEP) Trial(MMEP) | terminated | Phase 2 | 24 | University of MiamiOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours | terminated | Phase 1 / Phase 2 | 92 | AHS Cancer Control AlbertaOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 110 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT02664961 | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | terminated | Phase 2 | 3 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01420965 | Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer | terminated | Phase 2 | 7 | Augusta UniversityOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | terminated | Phase 2 | 20 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | terminated | Phase 2 | 5 | Region SkaneOTHER | 1 | Jun 21, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01958112 | GSK1120212+GSK2141795 for Cervical Cancer | terminated | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT01118351 | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT01342172 | Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01994590 | Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 6 | Mar 11, 2019 | clinicaltrials |
| NCT02584400 | Tumor Hypoxia With HX4 PET in Several Diseases(HX4 SD) | terminated | Phase 2 | 1 | Maastricht Radiation OncologyOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02459912 | Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer(POTENT-C) | terminated | Phase 2 | 1 | NYU Langone HealthOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT01251354 | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy | terminated | Phase 2 | 6 | IpsenINDUSTRY | 2 | Jan 14, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 | clinicaltrials |
| NCT01420081 | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer | terminated | Phase 2 | 67 | PfizerINDUSTRY | 8 | Jan 8, 2019 | clinicaltrials |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 18 | PfizerINDUSTRY | 2 | Jan 8, 2019 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00526591 | Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer | terminated | Phase 2 | 17 | Jorge A. Garcia, MDOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02560038 | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | terminated | Phase 2 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT02560051 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | terminated | Phase 2 | 19 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT02494713 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00414076 | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy | terminated | Phase 2 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00103376 | Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 23 | Medical University of South CarolinaOTHER | 1 | Nov 5, 2018 | clinicaltrials |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | terminated | Phase 2 | 6 | Western Regional Medical CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00080782 | Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00672009 | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | terminated | Phase 2 | 11 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01354951 | Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Oct 9, 2019source: clinicaltrials